Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Heidelberg – page 80

1 132 clinical trials in Heidelberg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Heidelberg at a glance
1 132
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 132 trials in Heidelberg

Open in trial search

Neoplasm malignant

Not recruiting

Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Pulmonary arterial hypertension

Not recruiting

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Neuroendocrine carcinoma

Not recruiting

Study of Cabozantinib and Avelumab for Patients with Advanced Neuroendocrine Tumors G3 Resistant to Standard Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Squamous cell carcinoma of skin

Not recruiting

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Endometrial cancer+5

Not recruiting

A Phase 1/2a Study of BNT142 Safety and Early Effectiveness in Patients with Advanced Solid Tumors Expressing CLDN6 Protein

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:BioNTech SE

Renal cell carcinoma

Not recruiting

Study of Belzutifan and Palbociclib for Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Medulloblastoma

Not recruiting

Study on Personalized Treatment for Post-Pubertal Patients with Newly Diagnosed Medulloblastoma Using Sonidegib, Cisplatin, Lomustine, and Vincristine

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Heidelberg

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on heart failure prevention and treatment of TTR amyloidosis cardiovascular complications. Studies evaluating new therapeutic approaches for pulmonary hypertension.

  • Heart Disease Prevention
  • Cardiovascular Safety Studies
  • Amyloidosis Treatment

Research includes evaluation of novel compounds for heart conditions and preventive therapies.

02 Oncology Studies

Comprehensive research in lung cancer, bladder cancer, and melanoma treatments. Advanced trials for various lymphomas and leukemias using innovative therapeutic approaches.

  • Non-Small Cell Lung Cancer
  • Hematological Malignancies
  • Immunotherapy Combinations

Focus on targeted therapies and immunological approaches in cancer treatment.

03 Transplant Medicine

Groundbreaking research in kidney transplantation with innovative immune system modification approaches. Studies exploring new methods to improve transplant outcomes.

  • Living Donor Procedures
  • Immune System Modulation
  • Post-Transplant Care

Emphasis on developing personalized immunosuppression strategies.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.